June 18, 2018 09:46 AM EDTUpdated June 19, 11:52 AM

Seven biotech IPOs ready to roll; Celltrion's Herceptin biosim gets second review at FDA

John Carroll

Editor & Founder

→ Renaissance Capital is tracking 7 new biotech IPOs this week. The lineup includes Magenta, Avrobio and Autolus, all high-profile ventures that will be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seven biotech IPOs ready to roll; Celltrion's Herceptin biosim gets second review at FDA

John Carroll

Editor & Founder

Sign up to read this article for free.

Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future

Exclusive: Two Vida Ventures co-founders exit the VC firm

Early data on BTK degraders suggest promise of next-gen approach

J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of 10’ patients

'It's the biology, stupid': Relation and GSK team up on fibrosis, osteoarthritis

The key to faster, more impactful research? Put patients in the driver’s seat

Sev­en biotech IPOs ready to roll; Cell­tri­on's Her­ceptin biosim gets sec­ond re­view at FDA

John Carroll

Editor & Founder

Sign up to read this article for free.

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

'It's the bi­ol­o­gy, stu­pid': Re­la­tion and GSK team up on fi­bro­sis, os­teoarthri­tis

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Seven biotech IPOs ready to roll; Celltrion's Herceptin biosim gets second review at FDA

Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future

Exclusive: Two Vida Ventures co-founders exit the VC firm

Early data on BTK degraders suggest promise of next-gen approach

J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of 10’ patients

'It's the biology, stupid': Relation and GSK team up on fibrosis, osteoarthritis

The key to faster, more impactful research? Put patients in the driver’s seat